Katabi Maha's Form 4 filing
Vera Therapeutics, Inc. (VERA) · filed Feb 8, 2023
- Accession no.
- 0001104659-23-014661
- Filed
- Feb 8, 2023, 6:29 PM ET
- Trade date
- Feb 6, 2023
- Filing delay
- 2 days
- Rule 10b5-1 plan
- Not on the form (before 2023)
This filing lists 1 non-derivative transaction. Open-market purchases total $2.00M. It was filed 2 days after the trade.
Reporting owners
A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.
| Owner | Relationship to the company |
|---|---|
| Katabi MahaCIK 0001720685 | Director, 10% Owner |
| Healy JamesCIK 0001245624 | 10% Owner |
| Sofinnova Management X, L.P.CIK 0001680194 | 10% Owner |
| Sofinnova Venture Partners X, L.P.CIK 0001680200 | 10% Owner |
| Sofinnova Management X-A, L.L.C.CIK 0001965187 | 10% Owner |
Non-derivative securities (Table I)
Acquisitions and disposals of common stock and similar shares, one row per line on the filing.
| Trade date | Security | Transaction | Shares | Price | Value | Shares after | Ownership | Flags |
|---|---|---|---|---|---|---|---|---|
| Feb 6, 2023 | Class A Common Stock | PPurchaseAcquired | +285,714 | $7.00 | +$1,999,998 | 3,467,156 | Direct |
Footnotes and remarks
Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.
No transaction price on this filing refers to a footnote.